Stephen L Chan
Overview
Explore the profile of Stephen L Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
10920
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yap D, Chan G, Ho S, Wong R, Chan S, Lee V, et al.
Hum Vaccin Immunother
. 2025 Mar;
21(1):2463185.
PMID: 40063340
Patients with acquired immunocompromising conditions face considerable risk of developing herpes zoster (HZ). Based on the underlying medical conditions and degree of immune dysfunction, these patients require tailored strategies for...
2.
3.
Chan L, Kwong T, Yau J, Chan S
Ann Hepatol
. 2025 Feb;
:101781.
PMID: 39929474
Immunotherapy has revolutionized the treatment landscape for advanced HCC, resulting in prolonged response and improved survival. With these results, a pressing question arises: what is the optimal treatment following first-line...
4.
Mok K, Chen O, Yau J, Chan L, Chan S
Expert Opin Emerg Drugs
. 2025 Jan;
PMID: 39834011
No abstract available.
5.
Sangro B, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, et al.
Lancet
. 2025 Jan;
405(10474):216-232.
PMID: 39798579
Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed...
6.
Lau G, Obi S, Zhou J, Tateishi R, Qin S, Zhao H, et al.
Hepatol Int
. 2024 Nov;
18(6):1661-1683.
PMID: 39570557
In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs...
7.
Chan L, Wong V, Chan S
NEJM Evid
. 2024 Oct;
3(11):EVIDe2400344.
PMID: 39437134
No abstract available.
8.
Prinzi F, Salani F, Rimini M, Rizzato M, Antonuzzo L, Camera S, et al.
Oncologist
. 2024 Oct;
PMID: 39427227
Background: In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our...
9.
Kim G, Lim Y, Han S, Choi G, Choi W, Choi J, et al.
Ann Intern Med
. 2024 Sep;
177(10):1308-1318.
PMID: 39284185
Background: A nonlinear association between serum hepatitis B virus (HBV) DNA levels and hepatocellular carcinoma (HCC) risk has been suggested in patients with chronic hepatitis B (CHB). Objective: To develop...
10.
Zhu G, Jiang P, Li X, Peng W, Choy L, Yu S, et al.
Clin Chem
. 2024 Aug;
70(11):1355-1365.
PMID: 39206580
Background: Cell-free DNA (cfDNA) analysis offers an attractive noninvasive means of detecting and monitoring diseases. cfDNA cleavage patterns within a short range (e.g., 11 nucleotides) have been reported to correlate...